Belfast Health and Social Care Trust
caring supporting improving together

FOI/38517

21 October 2026

Non-Small Cell Lung Cancer Patients treated in past 3 months (October 2026)

How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
  5
- **Amivantamab Monotherapy**
  0
- **Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only)**
  <5
- **Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel**
  0
- **Atezolizumab monotherapy (subcutaneous injection only)**
  0
- **Dabrafenib + Trametinib**
  0
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin**
  0
- **Durvalumab**
  5
- **Gemcitabine**
  0
- **Nintedanib + Docetaxel**
  0
- **Nivolumab**
  0
- **Osimertinib**
  6

- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
  0

- **Paclitaxel**
  0

- **Pembrolizumab Monotherapy**
  25

- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
  0

- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)**
  7

- **Pemetrexed + Platinum (Carboplatin/Cisplatin)**
  0

- **RET Inhibitors (Pralsetinib, Selpercatinib)**
  <5

- **Sotorasib**
  <5

- **Tepotinib**
  0

- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin**
  23

- **Other active systemic anti-cancer therapy**
  Gemcitabine+Carboplatin
  5

  Osimertinib+Pemetrexed/Carboplatin
  <5

  Paclitaxel+Carboplatin
  <5

  Paclitaxel+Carboplatin XRT
  8

  Pembrolizumab SC Gemcitabine/Carboplatin
  <5

  Pembrolizumab SC Pemetrexed/Carboplatin
  <5

Palliative care only

Belfast Trust does not collect or record this information. Therefore, the requested information is not held for the purposes of the Freedom of Information Act 2000 and cannot be provided.

- **Amivantamab with carboplatin and pemetrexed**
  0

- **Cemiplimab with platinum-based chemotherapy**
  0

- **Adagrasib**
  0

- **Datopotamab deruxtecan**
  0

- **Amivantamab with Lazertinib**
  0

- **Pembrolizumab subcutaneous injection**
  23

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.